Combined therapy for urologic cancer cells by high-intensity focused ultrasound and PEG-conjugated fullerene
Project/Area Number |
22591783
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Aichi Medical University (2011-2012) National Defense Medical College (2010) |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
ASANO Tomohiko 防衛医科大学校, 医学教育部医学科専門課程, 教授 (40167226)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | ポリエチレングリコール / フラーレン / 癌細胞株 / 収束超音波 / 抗腫瘍効果 / 担癌マウス / ポリエチレングリコール(PEG) |
Research Abstract |
By chemically modifying fullerene (C60) with polyethylene glycol (PEG), we succeeded in synthesizing water-soluble PEG-conjugated fullerene. MTS assays showed that thecombination of HIFU with PEG-conjugated fullerene resulted in synergistic growth inhibitory effects in PC-3 cells in vitro. In vivo, however, we failed to confirm reproducibility on the results of selective tumor tissue accumulation of fullerene because of instability of labeled PEG-conjugated fullerene. Using chicken tissue model we found synergistic tissue degenerating effects by this combination therapy, which showed no additive or synergistic antitumor effects in PC-3 xenograft models.
|
Report
(4 results)
Research Products
(2 results)